[Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer]

Autor:	J, Morote Robles, C, Reig Ruiz, J, Vila Barja, M A, López Pacios, J A, de Torres Mateos, A, Soler Roselló
Rok vydání:	1993
Předmět:	Aged 80 and over Male Prostatic Neoplasms Androgen Antagonists Bone Neoplasms Middle Aged Prostate-Specific Antigen Combined Modality Therapy Sensitivity and Specificity Humans Radionuclide Imaging Orchiectomy Aged Follow-Up Studies Retrospective Studies
Zdroj:	Actas urologicas espanolas. 17(5)
ISSN:	0210-4806
Popis:	Analysis of the evolution of 78 patients with hormonally-treated non-metastatic prostate cancer. During an average follow-up of 62.3 months, local clinical and metastatic progression in 14.1% and 7.7% cases, respectively, was observed. Overall, PSA detected progression of disease in 94.1% cases, with an anticipation which range between 4 and 52 months. Evidence of bone metastatic progression was confirmed in 2.1% of the 286 scintigraphies performed. Following analysis of results, by accepting their indication from a PSA level higher than 100 ng/ml, 97.9% would have been avoided, achieving a 100% sensitivity and 94.1% diagnostic efficacy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::5b1ad39a13503f6ddc2dd38844c52e5d https://pubmed.ncbi.nlm.nih.gov/7688176 Zobrazit plný text záznamu